Liu et al. administered an antagomiR to inactivate the TGFβ/SMAD and the Wnt/β-catenin signaling pathways in esophageal squamous cell carcinoma (ESCC) [54]. Here, TGFB1 is linked to esophageal squamous cell carcinoma.